trial · primary record
Pasritamig
Prostatic Neoplasms, Castration-Resistant
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 800 |
| Primary completion | 2030-06-07 |
| Primary endpoint | Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT07225946 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:56:15.794Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07225946
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pasritamig · compound